Givinostat

• CAT Number: I003748
• CAS Number: 497833-27-9
• Molecular Formula: C24H27N3O4
• Molecular Weight: 421.49
• Purity: ≥95%
• Target: Epigenetics
• Solubility: ≥95 mg/mL in DMSO, ≥2 mg/mL in H2O
• Storage: 0 - 4℃
• IC50: 10 nM (for HD2), 7.5 nM (for HD1-B), 16 nM (for HD1-A)
• IUPAC Name: [6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate
• InChI: InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
• InChIKey: YALNUENQHAQXEA-UHFFFAOYSA-N
• SMILES: CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO

Givinostat（Cat No.:I003748）is an investigational drug primarily being studied for its potential to treat Duchenne muscular dystrophy (DMD) and other muscle-wasting conditions. It is a histone deacetylase (HDAC) inhibitor, which works by modifying gene expression to reduce inflammation and fibrosis, potentially improving muscle function and slowing disease progression. Givinostat has shown promise in clinical trials by targeting multiple pathways involved in muscle degeneration, offering hope for a disease-modifying therapy. Side effects may include gastrointestinal disturbances, headache, and fatigue, though its safety and efficacy are still under evaluation in various clinical studies.